Nattokinase

Natto protease: Fibrin ↓, thrombolysis ↑, platelet ↓; preclinical anti-metastatic rationale in ovarian/colorectal/prostate/lung.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Moderate — Strong fibrinolytic/antithrombotic evidence; oncology benefits remain largely preclinical and inferential.NKNatto enzyme

Forms: Capsules (2000-4000 FU) · Enteric-coated tablets for stability

Educational only, not medical advice. OncoForge makes no claim that Nattokinase treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Clot-dissolving protease from natto that degrades fibrin and enhances plasmin activity, potentially disrupting platelet–fibrin cloaking that aids metastasis. Oncology data are mostly preclinical; bleeding risk is the major clinical concern.

Evidence at a glance

Tier 1 · labOvarianColorectalProstateLung

Robust CV thrombolytic trials; oncology confined to preclinical CTC/metastasis models; no dedicated RCTs; inferential from fibrin role in seeding.

How it may work

Nattokinase (subtilisin-like serine protease) directly cleaves fibrin and increases endogenous fibrinolysis (plasmin generation), while modestly inhibiting platelet aggregation and improving microcirculation. By dismantling fibrin/platelet scaffolds, it might reduce tumor cell adhesion and vascular trapping; however, controlled human oncology trials are scarce.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Fibrin↓Direct cleavage and plasmin enhancement
Thrombolysis↑Clot dissolution and microcirculation improvement
Platelet↓Aggregation inhibition
Metastasis Support↓Fibrin/platelet cloaking disruption

FibrinThrombolysisPlateletMetastasis

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Cisplatin: Mitigates vascular complications in ovarian therapy.
Curcumin: Additive fibrin/platelet effects in colorectal models.
Resveratrol: Cooperative anti-thrombotic in prostate cancer.
Quercetin: Enhanced CTC disruption in lung preclinical.

Overlapping mechanisms

Fibrinolysis: Overlaps with lumbrokinase/serapeptase; bleeding additive.
Platelet ↓: Redundant with aspirin/omega-3; monitor hemostasis.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Bleeding RiskGi UpsetAllergy Risk

Potential interactions

anticoagulantsContraindicateHighTheoreticalSynergistic bleeding risk (e.g., warfarin, DOACs).
antiplateletsCautionHighTheoreticalAdditive effects (e.g., aspirin, clopidogrel).
CisplatinSynergizeLowTheoreticalReduces treatment-related thrombosis.

Timing

Empty-stomach: Maximizes absorption and activity.
BID: Divided for steady fibrinolysis.

References

Research

No published studies for Nattokinase yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Nattokinase depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 2000–4000 FU/day (po) divided doses; empty stomach, Cardio 2000 FU/day; adjunct 2000-4000 FU; enteric-coated for GI stability; cycle if bleeding concerns..

Trials studying Nattokinase

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar